Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | CTSB | P07858 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 7/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30074880 | 1.00 | PTGES (0.49) | PTGESALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL358629 | 0.88 | MAPT (0.45) | PTGESALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL31424455 | 0.84 | PTGES (0.51) | PTGESMEN1MAPTKMT2AEGFR | |
| SCHEMBL30074833 | 0.82 | PTGES (0.49) | PTGESMAPTEGFRLMNA | |
| SCHEMBL5767153 | 0.82 | GPR35 (0.46) | ALDH1A1MEN1MAPTKMT2AKDM4E | |
| SCHEMBL26620010 | 0.82 | PTGES (0.49) | PTGESALDH1A1MAPTCTSBEGFR | |
| SCHEMBL2249257 | 0.82 | TSHR (0.45) | ALDH1A1MEN1MAPTKMT2AKDM4E | |
| SCHEMBL202476 | 0.82 | PTGES (0.49) | PTGESMAPTEGFRLMNA | |
| SCHEMBL5766464 | 0.82 | TDP1 (0.45) | ALDH1A1MEN1MAPTKMT2AKDM4E | |
| SCHEMBL3865236 | 0.78 | CRHBP (0.53) | ALDH1A1MEN1MAPTKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492200-B2 | NLRP3 modulators | Birstol Myers-Squibb Company (US) | 2025-12-09 | — | — | US | disclosed |
| EP-3921322-B1 | PHOSPHORUS IMIDAZOQUINOLINE AMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF | CANWELL BIOTECH LTD (HK) | 2025-09-03 | — | — | EP | disclosed |
| US-12351580-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| WO-2025103490-A1 | N-OXIDE IMMUNE AGONISTS ACTIVATION BY RADIOTHERAPY | Beijing Changping Laboratory (CN) | 2025-05-22 | — | — | WO | disclosed |
| EP-3793613-B1 | IMMUNOCONJUGATES | BOLT BIOTHERAPEUTICS INC (US) | 2025-01-01 | — | — | EP | disclosed |
| CN-110325534-B | Substituted imidazoquinolines as NLRP3 modulators | 先天肿瘤免疫公司 | 2024-04-05 | — | — | CN | disclosed |
| US-11932663-B2 | Phosphorus imidazoquinoline amine derivatives, pharmaceutical compositions and therapeutic methods thereof | CANWELL BIOTECH LIMITED (CN) | 2024-03-19 | — | — | US | disclosed |
| US-20240067649-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067649-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067649-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2024-02-29 | — | — | US | disclosed |
| EP-1653914-A2 | OXIME SUBSTITUTED IMIDAZO-CONTAINING COMPOUNDS | 3M Innovative Properties Company (US) | 2006-05-10 | — | — | EP | disclosed |
| CN-1747953-A | Aryl / hetaryl substituted imidazoquinolines. | 3M INNOVATIVE PROPERTIES CO (US) | 2006-03-15 | — | — | CN | disclosed |
| WO-2005123080-A2 | NITROGEN-CONTAINING HETEROCYCLYL SUBSTITUTED IMIDAZOQUINOLINES AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-12-29 | — | — | WO | disclosed |
| EP-1590348-A1 | ARYL / HETARYL SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2005-11-02 | — | — | EP | disclosed |
| WO-2005048933-A2 | OXIME SUBSTITUTED IMIDAZO RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005048945-A2 | HYDROXYLAMINE SUBSTITUTED IMIDAZO RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005018551-A2 | OXIME SUBSTITUTED IMIDAZO-CONTAINING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005018556-A2 | HYDROXYLAMINE SUBSTITUTED IMIDAZO-CONTAINING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20040147543-A1 | Aryl substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-07-29 | — | — | US | disclosed |
| WO-2004058759-A1 | ARYL / HETARYL SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11932663-B2 | Phosphorus imidazoquinoline amine derivatives, pharmaceutical compositions and therapeutic methods thereof | TLR8, TLR7, TLR9 | PTGES 1506/4885ALDH1A1 4104/4885MEN1 3328/4885 |
| US-12492200-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | PTGES 419/4885ALDH1A1 864/4885MEN1 3090/4885 |
| US-12351580-B2 | NLRP3 modulators | NLRP3, NLRP1, NOD1 | PTGES 2479/4885ALDH1A1 3584/4885MEN1 3939/4885 |
| US-20240067649-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, NOD1 | PTGES 2479/4885ALDH1A1 3584/4885MEN1 3939/4885 |
| US-20040147543-A1 | Aryl substituted imidazoquinolines | IL2, IFNG, IRF3 | PTGES 296/4885ALDH1A1 730/4885MEN1 4521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.